XERIS PHARMATICALS ($XERS) posted quarterly earnings results on Thursday, May 8th. The company reported earnings of -$0.06 per share, missing estimates of -$0.05 by $0.01. The company also reported revenue of $60,120,000, beating estimates of $58,761,690 by $1,358,310.
You can see Quiver Quantitative's $XERS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
XERIS PHARMATICALS Insider Trading Activity
XERIS PHARMATICALS insiders have traded $XERS stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $XERS stock by insiders over the last 6 months:
- BETH HECHT (See Remarks) sold 40,000 shares for an estimated $217,244
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
XERIS PHARMATICALS Hedge Fund Activity
We have seen 93 institutional investors add shares of XERIS PHARMATICALS stock to their portfolio, and 48 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAXTON CORP removed 3,098,191 shares (-60.6%) from their portfolio in Q4 2024, for an estimated $10,502,867
- CENTERBOOK PARTNERS LP removed 2,791,929 shares (-80.2%) from their portfolio in Q4 2024, for an estimated $9,464,639
- AIGH CAPITAL MANAGEMENT LLC removed 2,574,846 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $14,135,904
- UBS GROUP AG added 1,451,239 shares (+512.3%) to their portfolio in Q4 2024, for an estimated $4,919,700
- WALLEYE CAPITAL LLC removed 1,121,738 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $3,802,691
- CITADEL ADVISORS LLC added 833,328 shares (+inf%) to their portfolio in Q4 2024, for an estimated $2,824,981
- GOLDMAN SACHS GROUP INC added 754,137 shares (+90.2%) to their portfolio in Q4 2024, for an estimated $2,556,524
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
XERIS PHARMATICALS Analyst Ratings
Wall Street analysts have issued reports on $XERS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Craig-Hallum issued a "Buy" rating on 03/07/2025
- H.C. Wainwright issued a "Buy" rating on 03/07/2025
To track analyst ratings and price targets for XERIS PHARMATICALS, check out Quiver Quantitative's $XERS forecast page.
XERIS PHARMATICALS Price Targets
Multiple analysts have issued price targets for $XERS recently. We have seen 2 analysts offer price targets for $XERS in the last 6 months, with a median target of $5.3.
Here are some recent targets:
- An analyst from Piper Sandler set a target price of $4.0 on 03/07/2025
- Oren Livnat from H.C. Wainwright set a target price of $6.6 on 11/11/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
